Dudediligence.

Avalo Therapeutics, Inc

AVTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$249,000Sep ’24$192,000Dec ’24$0.00Sep ’25$59,000Dec ’25
Net income, by quarter
$23.0MSep ’24−$35.3MDec ’24−$13.1MMar ’25−$20.8MJun ’25−$30.6MSep ’25−$13.7MDec ’25−$19.6MMar ’26−$36.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$5.4M$18.1M$1.9M$441,000$59,000
Gross profit$3.9M$14.6M$640,000none on filenone on file
Operating income−$82.1M−$37.4M−$27.4M−$68.5M−$72.9M
Net income−$84.4M−$41.7M−$31.5M−$35.1M−$78.3M
Operating cash flow−$70.9M−$26.8M−$30.7M−$49.1M−$51.5M
Free cash flow−$71.0M−$26.8M−$30.7M−$49.1Mnone on file
Cash$54.6M$13.2M$7.4M$134.5M$15.9M
Shares outstanding9.4M39.3K801.7K10.5M18.5M